Scleritis and other ocular side effects associated with pamidronate disodium

Frederick W. Fraunfelder, Frederick (Fritz) Fraunfelder, Bree Jensvold

Research output: Contribution to journalArticle

99 Citations (Scopus)

Abstract

PURPOSE: To evaluate reported cases of scleritis and other ocular side effects associated with pamidronate disodium, with emphasis on previously unreported cases of scleritis. DESIGN: Observational case series. METHODS: Case reports from the National Registry of Drug-Induced Ocular Side Effects (Casey Eye Institute), the Food and Drug Administration, the World Health Organization, and the literature were reviewed to determine possible adverse ocular side effects associated with pamidronate disodium. The World Health Organization's Causality Assessment Guide was used to categorize an adverse drug reaction. RESULTS: Seventeen cases of unilateral scleritis and one case of bilateral scleritis occurred, usually within 6 hours to 2 days after intravenous pamidronate disodium. Six patients had positive rechallenge testing with the scleritis occurring after a repeat drug exposure. Other ocular side effects with positive rechallenge data, associated with pamidronate disodium, include blurred vision, nonspecific conjunctivitis, ocular pain, bilateral anterior uveitis, and episcleritis. CONCLUSIONS: This is the first report, with rechallenge data, of any drug causing scleritis. Pamidronate disodium can cause vision-threatening diseases, which may require discontinuing the drug in some uveitis cases and, in this series, all cases of scleritis.

Original languageEnglish (US)
Pages (from-to)219-222
Number of pages4
JournalAmerican Journal of Ophthalmology
Volume135
Issue number2
DOIs
StatePublished - Feb 1 2003

Fingerprint

pamidronate
Scleritis
Pharmaceutical Preparations
Eye Pain
Anterior Uveitis
Conjunctivitis
Uveitis
United States Food and Drug Administration
Drug-Related Side Effects and Adverse Reactions
Causality

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Scleritis and other ocular side effects associated with pamidronate disodium. / Fraunfelder, Frederick W.; Fraunfelder, Frederick (Fritz); Jensvold, Bree.

In: American Journal of Ophthalmology, Vol. 135, No. 2, 01.02.2003, p. 219-222.

Research output: Contribution to journalArticle

@article{ffc3a5a3833d41baba99b79492970757,
title = "Scleritis and other ocular side effects associated with pamidronate disodium",
abstract = "PURPOSE: To evaluate reported cases of scleritis and other ocular side effects associated with pamidronate disodium, with emphasis on previously unreported cases of scleritis. DESIGN: Observational case series. METHODS: Case reports from the National Registry of Drug-Induced Ocular Side Effects (Casey Eye Institute), the Food and Drug Administration, the World Health Organization, and the literature were reviewed to determine possible adverse ocular side effects associated with pamidronate disodium. The World Health Organization's Causality Assessment Guide was used to categorize an adverse drug reaction. RESULTS: Seventeen cases of unilateral scleritis and one case of bilateral scleritis occurred, usually within 6 hours to 2 days after intravenous pamidronate disodium. Six patients had positive rechallenge testing with the scleritis occurring after a repeat drug exposure. Other ocular side effects with positive rechallenge data, associated with pamidronate disodium, include blurred vision, nonspecific conjunctivitis, ocular pain, bilateral anterior uveitis, and episcleritis. CONCLUSIONS: This is the first report, with rechallenge data, of any drug causing scleritis. Pamidronate disodium can cause vision-threatening diseases, which may require discontinuing the drug in some uveitis cases and, in this series, all cases of scleritis.",
author = "Fraunfelder, {Frederick W.} and Fraunfelder, {Frederick (Fritz)} and Bree Jensvold",
year = "2003",
month = "2",
day = "1",
doi = "10.1016/S0002-9394(02)01840-8",
language = "English (US)",
volume = "135",
pages = "219--222",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "2",

}

TY - JOUR

T1 - Scleritis and other ocular side effects associated with pamidronate disodium

AU - Fraunfelder, Frederick W.

AU - Fraunfelder, Frederick (Fritz)

AU - Jensvold, Bree

PY - 2003/2/1

Y1 - 2003/2/1

N2 - PURPOSE: To evaluate reported cases of scleritis and other ocular side effects associated with pamidronate disodium, with emphasis on previously unreported cases of scleritis. DESIGN: Observational case series. METHODS: Case reports from the National Registry of Drug-Induced Ocular Side Effects (Casey Eye Institute), the Food and Drug Administration, the World Health Organization, and the literature were reviewed to determine possible adverse ocular side effects associated with pamidronate disodium. The World Health Organization's Causality Assessment Guide was used to categorize an adverse drug reaction. RESULTS: Seventeen cases of unilateral scleritis and one case of bilateral scleritis occurred, usually within 6 hours to 2 days after intravenous pamidronate disodium. Six patients had positive rechallenge testing with the scleritis occurring after a repeat drug exposure. Other ocular side effects with positive rechallenge data, associated with pamidronate disodium, include blurred vision, nonspecific conjunctivitis, ocular pain, bilateral anterior uveitis, and episcleritis. CONCLUSIONS: This is the first report, with rechallenge data, of any drug causing scleritis. Pamidronate disodium can cause vision-threatening diseases, which may require discontinuing the drug in some uveitis cases and, in this series, all cases of scleritis.

AB - PURPOSE: To evaluate reported cases of scleritis and other ocular side effects associated with pamidronate disodium, with emphasis on previously unreported cases of scleritis. DESIGN: Observational case series. METHODS: Case reports from the National Registry of Drug-Induced Ocular Side Effects (Casey Eye Institute), the Food and Drug Administration, the World Health Organization, and the literature were reviewed to determine possible adverse ocular side effects associated with pamidronate disodium. The World Health Organization's Causality Assessment Guide was used to categorize an adverse drug reaction. RESULTS: Seventeen cases of unilateral scleritis and one case of bilateral scleritis occurred, usually within 6 hours to 2 days after intravenous pamidronate disodium. Six patients had positive rechallenge testing with the scleritis occurring after a repeat drug exposure. Other ocular side effects with positive rechallenge data, associated with pamidronate disodium, include blurred vision, nonspecific conjunctivitis, ocular pain, bilateral anterior uveitis, and episcleritis. CONCLUSIONS: This is the first report, with rechallenge data, of any drug causing scleritis. Pamidronate disodium can cause vision-threatening diseases, which may require discontinuing the drug in some uveitis cases and, in this series, all cases of scleritis.

UR - http://www.scopus.com/inward/record.url?scp=0037309091&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037309091&partnerID=8YFLogxK

U2 - 10.1016/S0002-9394(02)01840-8

DO - 10.1016/S0002-9394(02)01840-8

M3 - Article

VL - 135

SP - 219

EP - 222

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 2

ER -